Education
About Us
Working with TipRanks
Follow Us
Bioline RX Ltd Sponsored ADR (BLRX)
NASDAQ:BLRX
RESEARCH TOOLSreports
Top Page
Bioline RX Ltd Sponsored ADR
(NASDAQ:BLRX)
42Neutral
Positive Factors
Financial Performance
The company is on sounder financial footing following cessation of U.S. commercial operations, which resulted in an ~70% reduction in operating expenses.
Licensing and Partnerships
BioLineRx signed an exclusive agreement with Ayrmid Ltd for the development and commercialization of APHEXDA outside solid tumors and in territories.
Revenue and Sales
APHEXDA sales in the U.S. were $6 million for the year vs analyst estimate of $5.8 million.
Negative Factors
Clinical Trials and Data
Full enrollment in the Phase IIb trial of motixafortide in pancreatic ductal adenocarcinoma is not expected until 2027, and pancreatic cancer is a particularly intractable disease.
Revenue Forecast
Risk-adjusted revenue from motixafortide in metastatic pancreatic cancer has been removed, reducing the probability of success from 2.5% to 0%.
Stock Performance
The stock is expected to remain range bound until pipeline assets are in-licensed and/or motixafortide generates additional favorable data in pancreatic cancer and/or gene therapy indications.
Bioline RX Ltd Sponsored ADR (BLRX) vs. S&P 500 (SPY)
Market Cap
$10.43M
Dividend YieldN/A
Average Volume (3M)27.68K
Price to Earnings (P/E)―
Beta (1Y)1.47
Revenue Growth502.92%
EPS Growth88.01%
CountryUS
Employees28
SectorHealthcare
Sector Strength64
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.55
Shares Outstanding3,721,003
10 Day Avg. Volume24,105
30 Day Avg. Volume27,679
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.65
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$26.00Price Target Upside766.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bioline RX Ltd Sponsored ADR Business Overview & Revenue Model
Company DescriptionBioline RX Ltd Sponsored ADR (BLRX) is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of serious medical conditions. The company is primarily engaged in the discovery and clinical development of novel compounds, currently targeting areas such as oncology and immunology. Bioline RX operates through research and development activities and its lead product candidates are aimed at addressing unmet medical needs.
How the Company Makes MoneyBioline RX Ltd generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and royalties on sales generated from any successfully commercialized products. The company may also receive funding from grants or government support for its research endeavors. Bioline RX's financial performance is significantly influenced by the progress of its clinical trials, regulatory approvals, and the successful commercialization of its therapeutic candidates.
Bioline RX Ltd Sponsored ADR Financial Statement Overview
Summary
BLRX demonstrates growth in revenue but continues to face profitability challenges and relies heavily on borrowing, typical for a biotechnology firm in developmental stages. The current financial trajectory suggests a need for careful management of resources to achieve sustainable operations.Income Statement
BLRX showed a significant increase in revenue in the TTM (Trailing-Twelve-Months), growing from a low base. However, the company remains unprofitable with negative EBIT and net income margins, indicating ongoing operational challenges in achieving profitability.45
Neutral
Balance Sheet
The balance sheet reveals a high debt-to-equity ratio, suggesting leveraged operations, yet a reasonable equity ratio indicates some level of asset backing. The company's equity has decreased over recent periods, potentially impacting its financial stability.50
Neutral
Cash Flow
Free cash flow remains negative, reflecting cash burn, typical in biotechnology for research and development. This is offset by positive financing cash flows, indicating reliance on external funding. The operating cash flow to net income ratio shows divergence, highlighting cash flow challenges.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 21.99M | 4.80M | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 15.13M | 1.11M | -654.00K | -702.00K | -934.00K | -940.00K | EBIT |
| -27.84M | -49.69M | -29.16M | -24.78M | -22.93M | -28.11M | EBITDA |
| -12.36M | -57.06M | -28.50M | -25.35M | -21.99M | -27.17M | Net Income Common Stockholders |
| -19.92M | -60.61M | -18.87M | -28.14M | -30.93M | -26.81M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 25.97M | 42.99M | 51.08M | 57.13M | 22.59M | 27.49M | Total Assets |
| 29.34M | 63.92M | 76.38M | 81.39M | 47.29M | 53.57M | Total Debt |
| 109.56K | 11.59M | 12.32M | 4.65M | 7.68M | 10.46M | Net Debt |
| -8.58M | 7.34M | 1.74M | -8.34M | -9.15M | 5.16M | Total Liabilities |
| 6.81M | 50.70M | 25.54M | 13.30M | 25.26M | 20.19M | Stockholders Equity |
| 22.53M | 13.22M | 50.84M | 68.09M | 22.03M | 33.38M |
| Cash Flow | Free Cash Flow | ||||
| -30.35M | -22.91M | -26.56M | -23.67M | -23.21M | -22.74M | Operating Cash Flow |
| -30.27M | -22.61M | -26.24M | -23.57M | -23.21M | -22.67M | Investing Cash Flow |
| -2.18M | 1.44M | 4.01M | -38.22M | 16.67M | 5.26M | Financing Cash Flow |
| 33.51M | 15.06M | 20.44M | 57.75M | 17.87M | 19.19M |
Bioline RX Ltd Sponsored ADR Technical Analysis
Neutral
3.00
Price Trends
3.17
Negative
5.07
Negative
14.41
Negative
Market Momentum
-0.10
Negative
50.33
Neutral
86.81
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLRX, the sentiment is Neutral. The current price of 3 is above the 20-day moving average (MA) of 2.84, below the 50-day MA of 3.17, and below the 200-day MA of 14.41, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 50.33 is Neutral, neither overbought nor oversold. The STOCH value of 86.81 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BLRX.
Bioline RX Ltd Sponsored ADR Risk Analysis
Bioline RX Ltd Sponsored ADR disclosed 43 risk factors in its most recent earnings report. Bioline RX Ltd Sponsored ADR reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bioline RX Ltd Sponsored ADR Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $5.20B | 3.26 | -40.34% | 2.93% | 17.68% | 1.94% | |
47 Neutral | $12.85M | ― | -8.16% | ― | 35.25% | 81.05% | |
45 Neutral | $11.18M | 1.11 | -85.36% | ― | -70.05% | ― | |
43 Neutral | $13.12M | ― | -97.42% | ― | 234.31% | 79.88% | |
42 Neutral | $10.43M | ― | -69.11% | ― | 502.92% | 88.01% | |
38 Underperform | $8.49M | ― | -66.65% | ― | 157.63% | 40.52% | |
24 Underperform | $7.26M | ― | -490.03% | ― | ― | 99.64% |
* Healthcare Sector Average
Performance Comparison
BLRX
Bioline RX Ltd Sponsored ADR
3.00
-20.01
-86.96%
TXMD
TherapeuticsMD
1.14
-0.73
-39.04%
ABVC
ABVC BioPharma, Inc.
0.91
-0.68
-42.77%
APRE
Aprea Therapeutics
1.50
-3.85
-71.96%
ADXN
Addex Therapeutics
7.58
-7.83
-50.81%
RNAZ
TransCode Therapeutics
0.40
-16.92
-97.69%
Bioline RX Ltd Sponsored ADR Earnings Call Summary
Earnings Call Date: Mar 31, 2025 | % Change Since: -1.64% | Next Earnings Date: May 21, 2025
Earnings Call Sentiment Positive
The earnings call highlights BioLineRx's transformational licensing agreement and significant revenue growth, indicating a positive outlook with a strong financial position and promising clinical developments. However, the shutdown of U.S. operations and challenges in PDAC development highlight ongoing strategic adjustments.Highlights
Transformational Licensing Agreement with Ayrmid Pharma
BioLineRx executed an exclusive license agreement with Ayrmid Pharma Ltd. for motixafortide, generating $10 million in upfront payments and eligibility for $87 million in potential milestones, along with 18% to 23% sales royalties.
Significant Revenue Growth
Total revenues for 2024 were $28.9 million, a 502.1% increase from $4.8 million in 2023, driven by upfront payments and milestones from licensing agreements.
Operational Streamlining and Cost Reduction
BioLineRx reduced operating cash burn by approximately 70%, from over $40 million annually to about $12 million, following the shutdown of U.S. operations and headcount reduction in Israel.
Strong Financial Position
BioLineRx ended 2024 with $29 million in pro forma cash and a cash runway projected to fund operations through the second half of 2026.
Promising Clinical Developments in Sickle Cell Disease
Positive initial results from motixafortide trials in sickle cell disease, showing the potential to mobilize enough stem cells for gene therapies in fewer cycles.
Lowlights
Shutdown of U.S. Operations
BioLineRx shut down its U.S. operations as part of a strategic shift, impacting its commercial team and potentially reducing direct market engagement.
Challenges in PDAC Development
Development of motixafortide in pancreatic ductal carcinoma (PDAC) remains challenging, with full enrollment in the Phase 2b study not expected until 2027.
High Sales and Marketing Expenses
Sales and marketing expenses for 2024 were $23.6 million, only a slight decrease of 6.7% from 2023, despite the shutdown of U.S. commercial operations.
Company Guidance
During the BioLineRx Fourth Quarter and Full Year 2024 Financial Results Conference Call, CEO Phil Serlin highlighted key metrics reflecting the company's strategic shift and financial performance. BioLineRx executed an exclusive license agreement with Ayrmid Pharma Ltd. for motixafortide, generating $10 million in upfront payments and making the company eligible for $87 million in potential milestones and sales royalties ranging from 18% to 23%. The company reported total revenues of $28.9 million for 2024, a 502.1% increase from 2023. The shutdown of U.S. operations and headcount reduction in Israel reduced annual operating cash burn by 70%, from over $40 million to approximately $12 million. Additionally, BioLineRx ended the year with pro forma cash of $29 million and a cash runway projected to fund operations through the second half of 2026. The company is focused on expanding its pipeline by evaluating early clinical stage and late pre-clinical stage therapeutic assets in oncology and rare diseases, leveraging its drug development expertise.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.